RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia-Reference-Cited by-同舟云学术

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Published:2023-11-28 Issue:12 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Gaudet Daniel¹,Clifton Peter²,Sullivan David³,Baker John⁴,Schwabe Christian⁵,Thackwray Susan⁶,Scott Russell⁷,Hamilton James⁸,Given Bruce⁸,Melquist Stacey⁸,Zhou Rong⁸,Chang Ting⁸,San Martin Javier⁸,Watts Gerald F.⁹¹⁰,Goldberg Ira J.¹¹,Knowles Joshua W.¹²,Hegele Robert A.¹³,Ballantyne Christie M.¹⁴

Affiliation:

1. Department of Medicine, Université de Montréal and ECOGENE 21 Clinical Research Center, Chicoutimi, Quebec, QC, Canada

2. Royal Adelaide Hospital, Adelaide, SA, Australia

3. NSW Health Pathology, Royal Prince Alfred Hospital, Sydney

4. Middlemore Hospital, Auckland, New Zealand

5. Auckland Clinical Studies, Auckland, New Zealand

6. University of the Sunshine Coast, Sippy Downs, QLD, Australia

7. NZ Clinical Research, Christchurch, New Zealand

8. Arrowhead Pharmaceuticals, Inc., Pasadena, CA

9. School of Medicine, University of Western Australia, Perth, Australia

10. Department of Cardiology, Royal Perth Hospital, Perth, Australia

11. NYU Grossman School of Medicine, New York

12. Stanford Division of Cardiovascular Medicine and Cardiovascular Institute, School of Medicine, Stanford, CA

13. Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

14. Baylor College of Medicine, Houston

Publisher

Massachusetts Medical Society

Reference31 articles.

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

2. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia

3. Jacobsen A Savji N Blumenthal RS Martin SS. Hypertriglyceridemia management according to the 2018 AHA/ACC guideline. American College of Cardiology. 2019 (https://www.acc.org/latest-in-cardiology/articles/2019/01/11/07/39/hypertriglyceridemia-management-according-to-the-2018-aha-acc-guideline).

4. Triglycerides and cardiovascular disease

5. Clinical review on triglycerides

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia;New England Journal of Medicine;2024-09-12

2. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk;New England Journal of Medicine;2024-09-02

3. Safety and efficacy of the novel RNA interference therapies for hypertriglyceridemia and mixed hyperlipidemia management: a systematic review and meta-analysis;Endocrine Practice;2024-09

4. RNA interference therapy in cardiology: will new targets improve therapeutic goals?;Drugs in Context;2024-08-20

5. Walking the VLDL tightrope in cardiometabolic diseases;Trends in Endocrinology & Metabolism;2024-08